tetano
Editor, Senior Moderator
Sci Rep
. 2024 Mar 3;14(1):5218.
doi: 10.1038/s41598-024-55886-w. The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study
Dilşah Başkol Elik[SUP] 1 2 [/SUP], Şafak Kaya[SUP] 3 [/SUP], Sevil Alkan[SUP] 4 [/SUP], Tuna Demirdal[SUP] 5 [/SUP], Alper Sener[SUP] 4 5 [/SUP], Selçuk Kaya[SUP] 6 [/SUP], Özlem Güzel Tunçcan[SUP] 7 [/SUP], Bircan Kayaaslan[SUP] 8 [/SUP], Rahmet Güner[SUP] 8 [/SUP], Fatma Eser[SUP] 8 [/SUP], Hasip Kahraman[SUP] 9 [/SUP], Serhat Birengel[SUP] 10 [/SUP], Elif Mukime Sarıcaoğlu[SUP] 10 [/SUP], Esma Eroğlu[SUP] 11 [/SUP], Fatma Çölkesen[SUP] 11 [/SUP], Erman Öztürk[SUP] 12 [/SUP], Hande Berk Cam[SUP] 13 [/SUP], Çiğdem Mermutluoğlu[SUP] 14 [/SUP], Şafak Özer Balin[SUP] 15 [/SUP], Gülden Sincan[SUP] 16 [/SUP], Nilgün Altın[SUP] 17 [/SUP], Uluhan Sili[SUP] 18 [/SUP], Bedia Mutay Suntur[SUP] 19 [/SUP], Tuğba Arslan Gülen[SUP] 19 [/SUP], Burak Deveci[SUP] 20 [/SUP], Rabin Saba[SUP] 20 [/SUP], Şaban İncecik[SUP] 21 [/SUP], Gülden Eser Karlıdağ[SUP] 22 [/SUP], Elif Hakko[SUP] 23 [/SUP], Damla Akdağ[SUP] 24 [/SUP], Hüseyin Aytaç Erdem[SUP] 25 [/SUP], Hilal Sipahi[SUP] 26 [/SUP], Candan Çicek[SUP] 27 [/SUP], Mehmet Sezai Taşbakan[SUP] 28 [/SUP], Meltem Taşbakan[SUP] 25 [/SUP], Hüsnü Pullukçu[SUP] 25 [/SUP], Tansu Yamazhan[SUP] 25 [/SUP], Bilgin Arda[SUP] 25 [/SUP], Sercan Ulusoy[SUP] 25 [/SUP], Oguz Resat Sipahi[SUP] 25 29 [/SUP]
Affiliations
This multicentre (22 centres in Turkey) retrospective cohort study aimed to assess the clinical outcomes of patients with neutropenic fever and SARS-CoV-2 positivity. Study period was 15 March 2020-15 August 2021. A total of 170 cases (58 female, aged 59 ± 15.5 years) that fulfilled the inclusion criteria were included in the study. One-month mortality rate (OMM) was 44.8%. The logistic regression analysis showed the following significant variables for the mentioned dependent variables: (i) achieving PCR negativity: receiving a maximum of 5 days of favipiravir (p = 0.005, OR 5.166, 95% CI 1.639-16.280); (ii) need for ICU: receiving glycopeptide therapy at any time during the COVID-19/FEN episode (p = 0.001, OR 6.566, 95% CI 2.137-20.172), the need for mechanical ventilation (p < 0.001, OR 62.042, 95% CI 9.528-404.011); (iii) need for mechanical ventilation: failure to recover from neutropenia (p < 0.001, OR 17.869, 95% CI 3.592-88.907), receiving tocilizumab therapy (p = 0.028, OR 32.227, 95% CI 1.469-707.053), septic shock (p = 0.001, OR 15.4 96% CI 3.164-75.897), and the need for ICU (p < 0.001, OR 91.818, 95% CI 15.360-548.873), (iv) OMM: [mechanical ventilation (p = 0.001, OR 19.041, 95% CI 3.229-112.286) and septic shock (p = 0.010, OR 5.589,95% CI 1.509-20.700)]. Although it includes a relatively limited number of patients, our findings suggest that COVID-19 and FEN are associated with significant mortality and morbidity.
. 2024 Mar 3;14(1):5218.
doi: 10.1038/s41598-024-55886-w. The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study
Dilşah Başkol Elik[SUP] 1 2 [/SUP], Şafak Kaya[SUP] 3 [/SUP], Sevil Alkan[SUP] 4 [/SUP], Tuna Demirdal[SUP] 5 [/SUP], Alper Sener[SUP] 4 5 [/SUP], Selçuk Kaya[SUP] 6 [/SUP], Özlem Güzel Tunçcan[SUP] 7 [/SUP], Bircan Kayaaslan[SUP] 8 [/SUP], Rahmet Güner[SUP] 8 [/SUP], Fatma Eser[SUP] 8 [/SUP], Hasip Kahraman[SUP] 9 [/SUP], Serhat Birengel[SUP] 10 [/SUP], Elif Mukime Sarıcaoğlu[SUP] 10 [/SUP], Esma Eroğlu[SUP] 11 [/SUP], Fatma Çölkesen[SUP] 11 [/SUP], Erman Öztürk[SUP] 12 [/SUP], Hande Berk Cam[SUP] 13 [/SUP], Çiğdem Mermutluoğlu[SUP] 14 [/SUP], Şafak Özer Balin[SUP] 15 [/SUP], Gülden Sincan[SUP] 16 [/SUP], Nilgün Altın[SUP] 17 [/SUP], Uluhan Sili[SUP] 18 [/SUP], Bedia Mutay Suntur[SUP] 19 [/SUP], Tuğba Arslan Gülen[SUP] 19 [/SUP], Burak Deveci[SUP] 20 [/SUP], Rabin Saba[SUP] 20 [/SUP], Şaban İncecik[SUP] 21 [/SUP], Gülden Eser Karlıdağ[SUP] 22 [/SUP], Elif Hakko[SUP] 23 [/SUP], Damla Akdağ[SUP] 24 [/SUP], Hüseyin Aytaç Erdem[SUP] 25 [/SUP], Hilal Sipahi[SUP] 26 [/SUP], Candan Çicek[SUP] 27 [/SUP], Mehmet Sezai Taşbakan[SUP] 28 [/SUP], Meltem Taşbakan[SUP] 25 [/SUP], Hüsnü Pullukçu[SUP] 25 [/SUP], Tansu Yamazhan[SUP] 25 [/SUP], Bilgin Arda[SUP] 25 [/SUP], Sercan Ulusoy[SUP] 25 [/SUP], Oguz Resat Sipahi[SUP] 25 29 [/SUP]
Affiliations
- PMID: 38433274
- DOI: 10.1038/s41598-024-55886-w
This multicentre (22 centres in Turkey) retrospective cohort study aimed to assess the clinical outcomes of patients with neutropenic fever and SARS-CoV-2 positivity. Study period was 15 March 2020-15 August 2021. A total of 170 cases (58 female, aged 59 ± 15.5 years) that fulfilled the inclusion criteria were included in the study. One-month mortality rate (OMM) was 44.8%. The logistic regression analysis showed the following significant variables for the mentioned dependent variables: (i) achieving PCR negativity: receiving a maximum of 5 days of favipiravir (p = 0.005, OR 5.166, 95% CI 1.639-16.280); (ii) need for ICU: receiving glycopeptide therapy at any time during the COVID-19/FEN episode (p = 0.001, OR 6.566, 95% CI 2.137-20.172), the need for mechanical ventilation (p < 0.001, OR 62.042, 95% CI 9.528-404.011); (iii) need for mechanical ventilation: failure to recover from neutropenia (p < 0.001, OR 17.869, 95% CI 3.592-88.907), receiving tocilizumab therapy (p = 0.028, OR 32.227, 95% CI 1.469-707.053), septic shock (p = 0.001, OR 15.4 96% CI 3.164-75.897), and the need for ICU (p < 0.001, OR 91.818, 95% CI 15.360-548.873), (iv) OMM: [mechanical ventilation (p = 0.001, OR 19.041, 95% CI 3.229-112.286) and septic shock (p = 0.010, OR 5.589,95% CI 1.509-20.700)]. Although it includes a relatively limited number of patients, our findings suggest that COVID-19 and FEN are associated with significant mortality and morbidity.